|
|
Volumn 1, Issue 3, 2013, Pages 179-180
|
|
Outcome results renew debate about diabetes drug development
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ALOGLIPTIN;
ANTIDIABETIC AGENT;
PLACEBO;
ROSIGLITAZONE;
SAXAGLIPTIN;
ADAMANTANE;
DIPEPTIDE;
PIPERIDINE DERIVATIVE;
URACIL;
BRAIN ISCHEMIA;
CARDIOVASCULAR EFFECT;
CARDIOVASCULAR RISK;
DEATH;
DIABETES MELLITUS;
DIABETIC PATIENT;
DRUG EFFICACY;
DRUG INDUSTRY;
DRUG MARKETING;
DRUG SAFETY;
DRUG SYNTHESIS;
GLYCEMIC CONTROL;
HEART FAILURE;
HEART INFARCTION;
HOSPITALIZATION;
HUMAN;
NOTE;
OUTCOME ASSESSMENT;
PANCREAS CANCER;
PANCREATITIS;
PRESCRIPTION;
PRIORITY JOURNAL;
RISK BENEFIT ANALYSIS;
TREATMENT RESPONSE;
ANALOGS AND DERIVATIVES;
CARDIOVASCULAR DISEASES;
CLINICAL TRIAL (TOPIC);
COMPLICATION;
DIABETES MELLITUS, TYPE 2;
DRUG APPROVAL;
LEGISLATION AND JURISPRUDENCE;
PROCEDURES;
STANDARDS;
TREATMENT OUTCOME;
ADAMANTANE;
CARDIOVASCULAR DISEASES;
CLINICAL TRIALS AS TOPIC;
DIABETES MELLITUS, TYPE 2;
DIPEPTIDES;
DRUG APPROVAL;
HUMANS;
HYPOGLYCEMIC AGENTS;
PIPERIDINES;
TREATMENT OUTCOME;
URACIL;
|
|
EID: 84885956021
PISSN: 22138587
EISSN: None
Source Type: Journal
DOI: 10.1016/S2213-8587(13)70118-9 Document Type: Note |
|
Times cited : (3)
|
|
References (0)
|
